Article

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults

2022-04-06

Abstract excerpt

<h4>Background</h4> There is very little known about SARS-CoV-2 vaccine immune responses in New Zealand populations at greatest risk for serious COVID-19 disease. <h4>Methods</h4> This prospective cohort study assessed immunogenicity in BNT162b2 mRNA vaccine recipients in New Zealand without previous COVID-19, with enrichment for Māori, Pacific peoples, older adults ≥ 65 years of age, and those with co-morbidities...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7b1fa005-47f2-5afd-85c8-f25e834d79c1
DOI: 10.1101/2022.04.05.22273480

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adultsDOI 10.1101/2022.04.05.22273480Read

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 VaccineSemantic proximity Read

Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-upSemantic proximity Read

Age-related heterogeneity in immune responses to SARS-CoV-2 following BNT162b2 vaccinationSemantic proximity Read

Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical TrialSemantic proximity Read

Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after the third dose of BNT162b2 in healthy adolescentsSemantic proximity Read

Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccineSemantic proximity Read

Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity Read

BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian VariantSemantic proximity Read

Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2Semantic proximity Read

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 VariantSemantic proximity Read

Functional and quantitative evaluation of BNT162b2 SARS-CoV-2 vaccine-induced immunitySemantic proximity Read

Immune Response and Reactogenicity After Immunization With a Suboptimal Two-Dose mRNA Vaccine Followed by a Full Vaccination With a Standard mRNA Vaccine Compared to a Prime-Boost Regimen of a Standard mRNA Vaccine: A Multicenter Cohort StudySemantic proximity Read